Low-Dose REGN4461

Phase 2Small molecule

Regeneron

Low-Dose REGN4461 is one of 4 small molecule programs targeting Generalized Lipodystrophy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Generalized LipodystrophyActive, not recruiting

Generalized LipodystrophyPhase 2

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Generalized Lipodystrophy

#DrugCompanyPhaseTrials

Myalept

Chiesi Farmaceutici S.p.A.

Phase 3

1 2

Mibavademab

Regeneron

Phase 3

2 3

High-Dose REGN4461

Regeneron

Phase 2

1 4

Low-Dose REGN4461

Regeneron

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Generalized Lipodystrophy1 trial

Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy

Completed· Regeneron logo

Regeneron·Phase 2·NCT04159415·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Low-Dose REGN4461. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Low-Dose REGN4461 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Low-Dose REGN4461. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Regeneron company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Regeneron

Low-Dose REGN4461

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Generalized Lipodystrophy1 trial

References

Drug Info

Quick Facts

Related News